Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Consortium

Neither a doctor nor a teaching hospital

Research payments

$775,165

181 payments

Through program year 2025, Clinical Research Consortium is reported as receiving $775,165 in research payments, across 181 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $111 1
2024 Research $124 1
2023 Research $808 1
2022 Research $8,030 1
2021 Research $17,462 6
2020 Research $452,230 45
2019 Research $296,401 126

Breakdown

Who paid Research payments · program years 2019–2025
  1. Valneva Austria GmbH $349,584 10 payments
  2. Merck Sharp & Dohme Corporation $192,572 63 payments
  3. Vanda Pharmaceuticals Inc. $103,246 22 payments
  4. Genentech, Inc. $43,185 13 payments
  5. AstraZeneca Pharmaceuticals LP $41,478 6 payments
  6. Novartis Pharmaceuticals Corporation $16,605 6 payments
  7. Chiesi USA, Inc. $16,000 5 payments
  8. Teva Pharmaceuticals USA, Inc. $8,159 2 payments
  9. Radius Health, Inc. $2,034 29 payments
  10. Hexal AG $1,902 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $349,584 10 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $129,568 31 payments
  3. Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $103,246 22 payments
  4. Phii of Mstt1041a in Mod Severe Atopic Dermatitits $43,185 13 payments
  5. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $41,478 6 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN030 $34,717 9 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. $22,838 1 payment
  8. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $8,962 3 payments
  9. Ccd-05993Aa3-01 $8,900 3 payments
  10. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $8,159 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record